Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths globally. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for NSCLC, offering hope by reactivating the immune system to fight against tumor cells. Despite significant improvements in patient outcomes, the application of ICIs in NSCLC still faces numerous challenges, including variability in efficacy, complex mechanisms of resistance, and treatment-related toxicities. Understanding these aspects through comprehensive clinical and basic research is crucial for optimizing ICI therapy and improving patient survival rates. Therefore, this Research Topic aims to compile the latest research findings and perspectives on the multifaceted application and mechanisms of ICIs in NSCLC, fostering academic and clinical advancements.
To optimize the use of ICIs, it is crucial to deepen our understanding of their mechanisms of action, identify reliable biomarkers, and explore their interactions with the tumor immune microenvironment and microbiota. Thus, this Research Topic aims to gather cutting-edge research that elucidates these aspects, providing a comprehensive overview of the current state of ICI therapy in NSCLC. By showcasing studies on treatment efficacy, resistance mechanisms, the role of innate and adaptive immune cells, and potential combination therapies, we seek to foster a collaborative effort to enhance clinical strategies and contribute to improving patient outcomes and advancing the field of NSCLC immunotherapy.
We invite contributions that address the following themes:
• Efficacy Evaluation: Clinical trial data, real-world evidence, and comparative studies of different ICIs.
• Specific Populations: Efficacy and safety in elderly patients, smokers, and diverse racial and gender groups.
• Mechanisms of Action: Detailed studies on the biological mechanisms of PD-1/PD-L1, CTLA-4 pathways, and others.
• Resistance Mechanisms: Molecular bases of resistance and strategies to overcome it.
• Innate and Adaptive Immune Cells: Roles of NK cells, macrophages, dendritic cells, T cells, and B cells in ICI therapy.
• Biomarkers: Identification and validation of biomarkers for predicting ICI response and resistance.
• Microbiota: The relationship between microbiota and ICI efficacy/toxicity.
• Tumor Immune Microenvironment: Interactions and remodeling of the tumor microenvironment in response to ICIs.
• Combination Therapies: Efficacy and mechanisms of ICIs combined with other treatments.
We welcome original research articles, reviews, and case reports that provide novel insights and advancements in NSCLC immunotherapy.
Keywords:
Immune Checkpoint Inhibitors, Non-Small Cell Lung Cancer (NSCLC), Immunotherapy, Drug Resistance, Acquired Resistance, Biomarkers, Microbiota Combination Therapy, Tumor Immune Microenvironment, Microenvironment Remodeling, Innate Immune Cells, Adaptive Immune Cell
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths globally. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for NSCLC, offering hope by reactivating the immune system to fight against tumor cells. Despite significant improvements in patient outcomes, the application of ICIs in NSCLC still faces numerous challenges, including variability in efficacy, complex mechanisms of resistance, and treatment-related toxicities. Understanding these aspects through comprehensive clinical and basic research is crucial for optimizing ICI therapy and improving patient survival rates. Therefore, this Research Topic aims to compile the latest research findings and perspectives on the multifaceted application and mechanisms of ICIs in NSCLC, fostering academic and clinical advancements.
To optimize the use of ICIs, it is crucial to deepen our understanding of their mechanisms of action, identify reliable biomarkers, and explore their interactions with the tumor immune microenvironment and microbiota. Thus, this Research Topic aims to gather cutting-edge research that elucidates these aspects, providing a comprehensive overview of the current state of ICI therapy in NSCLC. By showcasing studies on treatment efficacy, resistance mechanisms, the role of innate and adaptive immune cells, and potential combination therapies, we seek to foster a collaborative effort to enhance clinical strategies and contribute to improving patient outcomes and advancing the field of NSCLC immunotherapy.
We invite contributions that address the following themes:
• Efficacy Evaluation: Clinical trial data, real-world evidence, and comparative studies of different ICIs.
• Specific Populations: Efficacy and safety in elderly patients, smokers, and diverse racial and gender groups.
• Mechanisms of Action: Detailed studies on the biological mechanisms of PD-1/PD-L1, CTLA-4 pathways, and others.
• Resistance Mechanisms: Molecular bases of resistance and strategies to overcome it.
• Innate and Adaptive Immune Cells: Roles of NK cells, macrophages, dendritic cells, T cells, and B cells in ICI therapy.
• Biomarkers: Identification and validation of biomarkers for predicting ICI response and resistance.
• Microbiota: The relationship between microbiota and ICI efficacy/toxicity.
• Tumor Immune Microenvironment: Interactions and remodeling of the tumor microenvironment in response to ICIs.
• Combination Therapies: Efficacy and mechanisms of ICIs combined with other treatments.
We welcome original research articles, reviews, and case reports that provide novel insights and advancements in NSCLC immunotherapy.
Keywords:
Immune Checkpoint Inhibitors, Non-Small Cell Lung Cancer (NSCLC), Immunotherapy, Drug Resistance, Acquired Resistance, Biomarkers, Microbiota Combination Therapy, Tumor Immune Microenvironment, Microenvironment Remodeling, Innate Immune Cells, Adaptive Immune Cell
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.